CoreCivic lifts 2026 diluted EPS view to $15.62-$15.82
Reuters2026/08/10 12:07- CoreCivic lifted 2026 diluted EPS guidance to $15.62-$15.82 from $15-$15.20, reflecting a $500 million accelerated share repurchase.
- Adjusted diluted EPS seen at $1.64-$1.73, up from $1.62-$1.70; FFO per diluted share forecast at $2.66-$2.75, up from $2.59-$2.68.
- Net income outlook cut to $1.49-$1.51 billion from $1.5-$1.52 billion; adjusted net income trimmed to $157-$165 million from $161.5-$169.5 million.
- Adjusted EBITDA forecast reduced to $434.5-$439.5 million from $440.5-$445.5 million; EBITDA seen at $2.22-$2.24 billion from $2.22-$2.24 billion.
- $500 million cash payment set for Aug. 10; initial delivery expected at 12 million shares; about $255.8 million repurchase capacity expected to remain.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Spot bitcoin ETFs pull in $987 million last week as institutional demand recovers
Silver Price Forecast: XAG/USD dips below $66.00 and hints at a bearish “H&S”
Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well
Swiss pharmaceutical giant Novartis has suffered another clinical trial setback—within one week, the company’s second major drug candidate has failed in a late-stage study. This latest disappointment concerns its potential blockbuster heart disease drug pelacarsen.
Crypto prices
More
